Status:
UNKNOWN
Sublingual Misoprostol With or Without Intravenous Tranexamic Acid During Hemorrhagic Cesarean Section
Lead Sponsor:
Aswan University Hospital
Conditions:
Cesarean Section Complications
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
Purpose to evaluates the effects of sublingual misoprostol with or without intravenous tranexamic acid (TA) on reducing post-partum hemorrhage during and after hemorrhagic cesarean section.
Detailed Description
Different uterotonic agents administration, mainly oxytocin, has been routinely used to reduce the frequency of cesarean section (CS) -related hemorrhage; however, some studies reported that oxytocin ...
Eligibility Criteria
Inclusion
- women who undergone elective cesarean section (C.S) and exposed to intraoperative bleeding about 500 ml diagnosed by visual analog estimation due to atonic uterus
- age between 18 and 45 years, gestational age of 37-40 weeks, singleton pregnancy, CS with inferior segment incision, and spinal anesthesia.
Exclusion
- having an underlying disease (heart, liver, kidney, pulmonary, etc.),
- eclampsia and severe preeclampsia
- allergy to TA (such as known allergy or thromboembolic event during pregnancy) and misoprostol
- coagulation disorders
- refuse or unable to consent
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03774706
Start Date
January 1 2019
End Date
January 31 2022
Last Update
February 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aswan University
Aswān, Egypt, 81528